This is a working overview of GHRH receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-30 and is reviewed periodically as new material appears.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
== The elements of instrumentation == Instrumentation includes sensing devices to measure process parameters such as pressure, temperature, liquid level, flow, velocity, composition, density, weight; and mechanical and electrical parameters such as vibration, position, power, current and voltage.
During the induction phase, electrolyte levels, glucose, blood counts, and liver and kidney function should be tested twice a week. In the consolidation phase, these tests should be performed weekly. Caution is advised in patients with kidney failure. During arsenic trioxide treatment, women of childbearing age and men capable of fathering children should use effective contraception. The impact of arsenic trioxide on fertility has not been thoroughly studied.
=== Release === Generally, a neurotransmitter is released via exocytosis at the presynaptic terminal in response to an electrical signal called an action potential in the presynaptic neuron. However, low-level "baseline" release also occurs without electrical stimulation. Neurotransmitters are released into and diffuse across the synaptic cleft, where they bind to specific receptors on the membrane of the postsynaptic neuron.
The most popular park in the city is Parco del Valentino. In 1961, during the celebrations of Italia61 (Italian unification centenary), an important international exhibition (FLOR61: Flowers of the world in Turin) took place in the park with 800 exhibitors from 19 countries. For the occasion the plan for the new lighting of the park, along with its fountains and paths, was assigned to Guido Chiarelli, the head engineer at the city hall.
== Measurements and tests == The nitrogen by o-phthaldialdehyde assay (NOPA) is used to measure available primary amino acids in grape juice using a spectrophotometer that can measure at 335 nm wavelength. Since the assay only measures primary amino acids, the results won't include proline or ammonia concentrations. Proline can be separately measured with an assay that uses ninhydrin to react with the amino acid in the presence of formic acid, yielding a compound that can be absorbed at 517 nm.
Sources: en.wikipedia.org
== Athletes who have deadlifted 1000 pounds or more == The following table lists the athletes who have achieved the feat. Although only the heaviest lift is mentioned for each athlete, the year they achieved the 1000 pound mark for the first time is also indicated. The list consists of both competition and training lifts. The all-time world record stands at 511 kg (1,126.56 lb), achieved by Mexico's Raul Flores.
By using life cycle assessment tools he demonstrated the shortcomings of bioplastics and similar biomass based technologies intended as a substitute for the petrochemical processes used today. His main findings showed that changing from petrochemical to biomass-based processes often worsens their environmental impact and increases the emissions of carbon dioxide when compared to conventional processes based on fossil fuel stocks. With the recent mandate to increase biofuel content in the United States this area of research has become increasingly important, but to date has failed to guide public policy in the United States. Arguably, Gerngross' most important biotechnological contribution consisted of humanizing the glycosylation machinery in yeast to produce human therapeutic proteins, including antibodies, with fully human carbohydrate structures. Much of this work was conducted at Glycofi, Inc., a Lebanon, New Hampshire biotechnology startup company that was acquired in 2006 by Merck in a record-setting $400 million transaction. His work has been frequently cited in the popular press including The Times (London), CNN, Scientific American, BBC, The Guardian, The Economist, New Scientist, Nature Biotechnology and the Los Angeles Times. He has most recently been covered by the Boston Globe, CNBC, First Rounders, Evaluate Pharma, STAT and numerous others.
Hypoglycemia due to endogenous insulin Congenital hyperinsulinism Transient neonatal hyperinsulinism (mechanism not known) Focal hyperinsulinism (KATP channel disorders) Paternal SUR1 mutation with clonal loss of heterozygosity of 11p15 Paternal Kir6.2 mutation with clonal loss of heterozygosity of 11p15 Diffuse hyperinsulinism KATP channel disorders SUR1 mutations Kir6.2 mutations Glucokinase gain-of-function mutations Hyperammonemic hyperinsulinism (glutamate dehydrogenase gain-of-function mutations) Short chain acyl coenzyme A dehydrogenase deficiency Carbohydrate-deficient glycoprotein syndrome (Jaeken's Disease) Beckwith-Wiedemann syndrome(suspected due to hyperinsulinism but pathophysiology uncertain: 11p15 mutation or IGF2 excess) Acquired forms of hyperinsulinism Insulinomas (insulin-secreting tumors) Islet cell adenoma or adenomatosis Islet cell carcinoma Adult nesidioblastosis Autoimmune insulin syndrome Noninsulinoma pancreatogenous hypoglycemia Reactive hypoglycemia (also see idiopathic postprandial syndrome) Gastric dumping syndrome Drug induced hyperinsulinism Sulfonylurea Aspirin Pentamidine Quinine Disopyramide Bordetella pertussis vaccine or infection D-chiro-inositol and myo-inositol Hypoglycemia due to exogenous (injected) insulin Insulin self-injected for treatment of diabetes (i.e., diabetic hypoglycemia) Insulin self-injected surreptitiously (e.g., Munchausen syndrome) Insulin self-injected in a suicide attempt or fatality Various forms of diagnostic challenge or "tolerance tests" Insulin tolerance test for pituitary or adrenergic response assessment Protein challenge Leucine challenge Tolbutamide challenge Insulin potentiation therapy Insulin-induced coma for depression treatment
=== Diagnostic criteria === An international group created a set of criteria for the diagnosis of primary Sjögren's disease in 2016 based on consensus around previous guidelines from the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR), which became known as the ACR-EULAR criteria. Although used primarily for recruitment into clinical trials, the criteria were shown to be effective in diagnosing Sjögren's by a 2025 Swedish cohort study. Per the ACR-EULAR criteria, a person with previously reported dry eye or dry mouth symptoms (including if responding positively to a short questionnaire) has SjD if they have a score of at least 4 when considering the following items:
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.